A detailed history of E Fund Management Co., Ltd. transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 12,752 shares of IONS stock, worth $480,495. This represents 0.03% of its overall portfolio holdings.

Number of Shares
12,752
Previous 10,255 24.35%
Holding current value
$480,495
Previous $488,000 4.51%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.06 - $51.86 $100,029 - $129,494
2,497 Added 24.35%
12,752 $510,000
Q2 2024

Aug 12, 2024

BUY
$36.45 - $47.7 $15,673 - $20,511
430 Added 4.38%
10,255 $488,000
Q1 2024

May 13, 2024

SELL
$42.03 - $53.55 $1,681 - $2,142
-40 Reduced 0.41%
9,825 $425,000
Q4 2023

Feb 06, 2024

SELL
$43.39 - $51.63 $53,413 - $63,556
-1,231 Reduced 11.09%
9,865 $499,000
Q3 2023

Nov 13, 2023

BUY
$38.5 - $47.13 $4,158 - $5,090
108 Added 0.98%
11,096 $503,000
Q2 2023

Aug 11, 2023

SELL
$34.73 - $43.33 $13,336 - $16,638
-384 Reduced 3.38%
10,988 $451,000
Q1 2023

May 11, 2023

BUY
$33.58 - $41.2 $3,358 - $4,120
100 Added 0.89%
11,372 $406,000
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $40,906 - $51,265
1,102 Added 10.84%
11,272 $426,000
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $88,682 - $118,097
-2,427 Reduced 19.27%
10,170 $450,000
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $135,179 - $183,309
4,263 Added 51.15%
12,597 $466,000
Q1 2022

May 12, 2022

BUY
$29.88 - $37.04 $170,853 - $211,794
5,718 Added 218.58%
8,334 $309,000
Q1 2021

May 12, 2021

BUY
$42.51 - $63.78 $111,206 - $166,848
2,616 New
2,616 $117,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.